Labcorp Holdings Inc. (LH)
NYSE: LH · Real-Time Price · USD
263.85
+2.35 (0.90%)
Aug 4, 2025, 4:00 PM - Market closed
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | 10.30B | 10.15B | 9.91B | 9.70B | 9.51B | 9.41B | 9.35B | 9.21B | ||||||||||||||||||||||
| Diagnostics Growth | 8.26% | 7.82% | 5.91% | 5.22% | 4.19% | 2.27% | -1.97% | -7.39% | ||||||||||||||||||||||
| Drug Development | 2.93B | 2.92B | 2.85B | 2.83B | 2.82B | 3.51B | 4.21B | 4.89B | ||||||||||||||||||||||
| Drug Development Growth | 3.87% | -16.80% | -32.26% | -42.15% | -50.00% | -38.45% | -27.06% | -15.94% |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Diagnostics | 1.62B | 1.61B | 1.60B | 1.60B | 1.57B | 1.59B | 1.62B | 1.68B | ||||||||||||||||||||||
| Diagnostics Growth | 3.08% | 0.95% | -1.48% | -4.68% | -12.13% | -21.44% | -32.72% | -38.97% | ||||||||||||||||||||||
| Drug Development | 466.00M | 459.00M | 437.20M | 425.30M | 422.50M | 446.50M | 546.00M | 647.70M | ||||||||||||||||||||||
| Drug Development Growth | 10.30% | 2.80% | -19.93% | -34.34% | -44.14% | -44.26% | -31.60% | -20.40% | ||||||||||||||||||||||
| General Corporate Expenses | -268.70M | -268.30M | -269.00M | -273.20M | -382.10M | -389.00M | -406.80M | -396.80M |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative | 2.27B | 2.23B | 2.17B | 2.12B | 2.07B | 2.12B | 2.12B | 2.11B | ||||||||||||||||||||||
| Selling, General, and Administrative Growth | 9.41% | 5.30% | 2.18% | 0.89% | -0.65% | 6.07% | 5.87% | 4.58% | ||||||||||||||||||||||
| Amortization | 265.90M | 256.40M | 245.20M | 237.20M | 226.50M | 235.70M | 237.10M | 246.60M | ||||||||||||||||||||||
| Amortization Growth | 17.40% | 8.78% | 3.42% | -3.81% | -13.38% | -9.10% | -18.69% | -22.60% | ||||||||||||||||||||||
| Restructuring and Other | 47.40M | 46.00M | 52.90M | 42.40M | 46.60M | 50.20M | 43.60M | 51.20M | ||||||||||||||||||||||
| Restructuring and Other Growth | 1.72% | -8.37% | 21.33% | -17.19% | -41.60% | -40.10% | -45.43% | -28.19% | ||||||||||||||||||||||
| Impairments | - | 5.30M | - | - | 349.30M | 349.00M | 285.50M | 275.30M | ||||||||||||||||||||||
| Impairments Growth | - | -98.48% | - | - | 28.18% | 28.55% | - | - |
Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.